3 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
Follow Alopecia universalis: new trials by email Literature Review of Alopecia universalis trials Research Report on Alopecia universalis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA PF-06651600, Placebo - Alopecia Areata | Phase 2 | Terminated | Pfizer | 71 | 2020-09-15 | 2025-07-11 |
| ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) ATI 502 0.46% Topical Solution - Alopecia Areata, Alopecia Universalis | Phase 2 | Terminated | Aclaris Therapeutics, Inc. | 56 | 2019-01-15 | 2020-10-06 |
| A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA) Placebo Cream, Ruxolitinib Phosphate Cream - Alopecia Areata | Phase 2 | Terminated | Incyte Corporation | 90 | 2015-11-18 | 2020-12-16 |
Alopecia Areata (3) · Alopecia (2)
Hair Diseases (3) · Hypotrichosis (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Pathological Conditions, Anatomical (2) · Pathological Conditions, Signs and Symptoms (2) · Alopecia (1)
PF-06651600 (1) · Solutions (1) · ruxolitinib (1)
Aclaris Therapeutics, Inc. (1) · Incyte Corporation (1) · Pfizer (1)
United States (3) · Australia (1) · Canada (1) · Poland (1)